20/20 Biolabs Inc.
20/20 Biolabs Inc. (AIDX): 2 pipeline candidates · ~10 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
10.2 months
D/E 1.19 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for 20/20 Biolabs Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.8M
Cash
$4.2M
Quarterly Burn
$1.3M
Runway
10.2 mo
Revenue
$353K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| onetest for cancer | Approved |
| onetest for longevity | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$50K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 16,227 | $31K |
| xtx topco ltd | 10,329 | $19K |
| toth financial advisory corp | 157 | $296 |
Frequently asked questions
How many drug candidates are in 20/20 Biolabs Inc.'s pipeline?
20/20 Biolabs Inc. (AIDX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is 20/20 Biolabs Inc.'s lead drug candidate?
20/20 Biolabs Inc.'s most advanced tracked candidate is onetest for cancer (Approved) for Multi-cancer early detection.
What is 20/20 Biolabs Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, 20/20 Biolabs Inc. has approximately 10.2 months of cash runway.
What is 20/20 Biolabs Inc.'s market capitalization?
20/20 Biolabs Inc.'s market capitalization is approximately $6.8M.
Who is the CEO of 20/20 Biolabs Inc.?
Mr. Jonathan Cohen is the chief executive officer of 20/20 Biolabs Inc. (AIDX).
Get the full picture on 20/20 Biolabs Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.